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background: Patients suffering from severe aortic stenosis and atrial fibrillation (AF) who undergo transcatheter valve replacement 
(TAVR) are at high risk for stroke and major bleeding. Left atrial appendage occlusion (LAAO), obviates the need for oral anticoagulation. 
Therefore, combining TAVR and LAAO makes sense. We investigate safety of combining TAVR and LAAO in the same sitting.
methods: 41 consecutive patients in AF underwent TAVR and LAAO in the same procedure (combined), using local anaesthesia and 
fluoroscopic guidance alone. The cohort was compared to 51 consecutive AF patients undergoing TAVR alone (single). As a primary safety 
endpoint at 30 days, a combination of all-cause mortality, stroke, life-threatening/disabling bleeding, acute kidney injury (Stage 2-3), major 
vascular complication, pericardial effusion/tamponade, device embolization, valve failure was chosen.
results: Mean age was 84±5 years. The median CHA2DS2-Vasc-score was 4.0 ± 1.05. The median HAS-BLED-score was 2.0 ± 0.95. 
The mean logistic EuroSCORE was 6.5±5.5. The primary endpoint occurred in 6 (14.6%) patients in the combined group and in 5 (9.8%) 
patients in the TAVI group (p= ns).
Conclusion:  Combining TAVR with LAAO is feasible and safe. In the intermediate and long run, it carries the potential to reduce stroke 
and bleeding complications in this high risk population. Future studies are needed to confirm an efficacy benefit.
 
